Following the approval of the world's first microbiome therapeutic by the U.S. Food and Drug Administration (FDA) in November last year, and with expectations that an oral microbiome therapeutic will soon be approved, interest in the related field is growing. In this context, the Korea Bio Association has organized a seminar together with domestic microbiome therapeutic companies.
The Bio Association announced on the 23rd that it will hold a "Microbiome Industry Seminar" on the 4th of next month at the Shinhan WAY Hall of Shinhan Investment Corp. in Yeouido, Yeongdeungpo-gu, Seoul. The seminar will introduce government policy support directions for microbiome therapeutics, clinical effects, and the latest development trends.
Key presentations include ▲ Introduction to the microbiome industry and policy trends (Kim Hyung-cheol, Bio PD, Korea Institute for Advancement of Technology) ▲ Current status of government operation of microbiome R&D projects (Lee Kwang-jun, Manager, Korea Disease Control and Prevention Agency) ▲ Microbiome: Will it become a leader opening a new spring for bio? (Park Jin-ho, Professor, Department of Family Medicine, Seoul National University Hospital) ▲ Microbiome: About brain diseases (Gut-brain axis) (Oh Beom-jo, Professor, Department of Family Medicine, Seoul National University Boramae Hospital) ▲ Global microbiome therapeutic trends and history (Wilhelm Holzapfel, Professor, Handong Global University) ▲ New methods for microbiome therapeutic production (Felix Faupel, CCO, BACTHERA) and more.
Through presentations by domestic and international experts, the Bio Association aims to review the development status and prospects of microbiome therapeutics, which have emerged as innovative next-generation biopharmaceuticals. The seminar will cover how far development has progressed, what clinical effects have been demonstrated, what technical obstacles remain to be overcome, and the future policy support directions that the Korean government should pursue. Only those who pre-registered, including pharmaceutical and bio analysts, fund managers, and journalists, will be allowed to attend. The event will be recorded on-site and later broadcast on the Bio Association's "BioTV" channel.
This seminar is co-hosted by five domestic microbiome therapeutic companies?CJ Bioscience, Genome & Company, Gobio Lab, Immunobiome, and HEM Pharma?and jointly sponsored by the Ministry of Trade, Industry and Energy, the Korea Disease Control and Prevention Agency, and Shinhan Investment Corp., under the organization of the Korea Bio Association.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
